Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | CA1 | P00915 | 2/20 | 0.78 |
| ▸ | CA2 | P00918 | 2/20 | 0.78 |
| ▸ | CA4 | P22748 | 2/20 | 0.78 |
| ▸ | CA12 | O43570 | 1/20 | 0.78 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.78 |
| ▸ | CA6 | P23280 | 1/20 | 0.78 |
| ▸ | CA7 | P43166 | 1/20 | 0.78 |
| ▸ | CA9 | Q16790 | 1/20 | 0.78 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL27652523 | 1.00 | HPGD (0.78) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL7299833 | 1.00 | HPGD (0.78) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL240023 | 1.00 | HPGD (0.78) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL29362663 | 0.89 | ALDH1A1 (1.00) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL29606432 | 0.89 | ALDH1A1 (1.00) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL29360246 | 0.89 | ALDH1A1 (1.00) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL1967 | 0.89 | ALDH1A1 (1.00) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL17156443 | 0.89 | ALDH1A1 (1.00) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL1509155 | 0.89 | ALDH1A1 (1.00) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL8433746 | 0.89 | ALDH1A1 (1.00) | HPGDKDM4EALDH1A1SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106983-A1 | SULFOXIDE AND SULFONE GLUCOKINASE ACTIVATORS AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-04-06 | — | — | US | disclosed |
| EP-4116290-A1 | PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME | Platefuse, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4013402-A1 | METHODS OF TREATING A SUBJECT WITH A CDC42-SPECIFIC INHIBITOR | Children's Hospital Medical Center (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3999053-A1 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | Children's Hospital Medical Center (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220061312-A1 | PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME | PLATEFUSE, INC. | 2022-03-03 | — | — | US | disclosed |
| US-11172673-B2 | Platelet storage methods and compositions for same | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2021034616-A1 | METHODS OF TREATING A SUBJECT WITH A CDC42-SPECIFIC INHIBITOR | CHILDREN' S HOSPITAL MEDICAL CENTER (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021011800-A1 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-01-21 | — | — | WO | disclosed |
| US-5985884-A | TREATMENT AND/OR PROPHYLAXIS OF DISEASES OR CONDITIONS IN WHICH INSULIN RESISTANCE IS THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISM SUCH AS TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDAEMIA, HYPERTENSION, CORONARY HEART DISEASE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-16 | — | — | US | disclosed |
| WO-1999019313-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-22 | — | — | WO | disclosed |
| WO-1999008501-A2 | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-02-25 | — | — | WO | disclosed |
| WO-1997041097-A2 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-11-06 | — | — | WO | disclosed |
| EP-0679084-A4 | — | — | 1995-11-08 | — | — | EP | disclosed |
| EP-0679084-A1 | HYDANTOIN AND SUCCINIMIDE-SUBSTITUTED DERIVATIVES OF SPIROINDANYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO. INC. (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1994014438-A1 | HYDANTOIN AND SUCCINIMIDE-SUBSTITUTED DERIVATIVES OF SPIROINDANYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| US-5137904-A | Useful in the treatment of atherosclerosis and thrombosis | G. D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0486280-A2 | Piperidinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1992007821-A1 | DIASTEREOISOMERS OF BICYCLO-SUBSTITUTED PHENYLACETONITRILE DERIVATIVES | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220061312-A1 | PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME | RHOA, ARHGDIB, ARHGDIA | HPGD 1710/4885KDM4E 3760/4885ALDH1A1 3922/4885 |
| US-11172673-B2 | Platelet storage methods and compositions for same | RHOA, ARHGDIB, ARHGDIA | HPGD 1710/4885KDM4E 3760/4885ALDH1A1 3922/4885 |
| US-20230106983-A1 | SULFOXIDE AND SULFONE GLUCOKINASE ACTIVATORS AND METHODS OF USE THEREOF | GCK, GCKR, KHK | HPGD 1293/4885KDM4E 1647/4885ALDH1A1 1082/4885 |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | HPGD 313/4885KDM4E 3509/4885ALDH1A1 487/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | HPGD 313/4885KDM4E 3509/4885ALDH1A1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.